176 related articles for article (PubMed ID: 20590752)
1. Saxagliptin efficacy.
Valiquette G
Diabetes Obes Metab; 2010 Aug; 12(8):734; author reply 735. PubMed ID: 20590752
[No Abstract] [Full Text] [Related]
2. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Borja-Hart NL; Whalen KL
Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
[TBL] [Abstract][Full Text] [Related]
3. Saxagliptin and tuberculosis.
Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
[No Abstract] [Full Text] [Related]
4. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz B
IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
[TBL] [Abstract][Full Text] [Related]
5. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
Jialal I; Dhindsa S
Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
[No Abstract] [Full Text] [Related]
6. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Gallwitz B
Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
[No Abstract] [Full Text] [Related]
7. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
Schwartz SL
Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
[TBL] [Abstract][Full Text] [Related]
8. Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
Shubrook JH; Colucci RA; Schwartz FL
Expert Opin Pharmacother; 2009 Dec; 10(17):2927-34. PubMed ID: 19929711
[TBL] [Abstract][Full Text] [Related]
9. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Deacon CF; Holst JJ
Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
[TBL] [Abstract][Full Text] [Related]
10. Metformin + saxagliptin for type 2 diabetes.
Scheen AJ
Expert Opin Pharmacother; 2012 Jan; 13(1):139-46. PubMed ID: 22149373
[TBL] [Abstract][Full Text] [Related]
11. FDA approves saxagliptin for type 2 diabetes.
Traynor K
Am J Health Syst Pharm; 2009 Sep; 66(17):1513. PubMed ID: 19710429
[No Abstract] [Full Text] [Related]
12. Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
Prescrire Int; 2011 Feb; 20(113):33-7. PubMed ID: 21488586
[TBL] [Abstract][Full Text] [Related]
13. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
Scherbaum WA
Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
[No Abstract] [Full Text] [Related]
14. Saxagliptin, alogliptin, and cardiovascular outcomes.
Scirica BM; Braunwald E; Bhatt DL
N Engl J Med; 2014 Jan; 370(5):483-4. PubMed ID: 24476444
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin + metformin. Mostly disadvantages.
Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
[No Abstract] [Full Text] [Related]
17. Choosing among the incretin agents and why it matters.
Unger J
J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
[No Abstract] [Full Text] [Related]
18. Saxagliptin: A Review in Type 2 Diabetes.
Dhillon S
Drugs; 2015 Oct; 75(15):1783-96. PubMed ID: 26403305
[TBL] [Abstract][Full Text] [Related]
19. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin (Onglyza) for type 2 diabetes.
Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
[No Abstract] [Full Text] [Related]
[Next] [New Search]
